文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症急性肠系膜缺血患者的抗凝管理与结局:一项国际研究

Anticoagulation management and outcomes in critically ill patients with acute mesenteric ischemia: an international study.
PubMed 文献 · Intensive Care Med · 2025-06-16
一句话结论ICU急性肠系膜缺血患者早期足量抗凝与30天生存率提高相关(53.5% vs 41.7%,NNT=8),出血并发症无差异。

该国际研究纳入19个国家33个ICU中心的370例急性肠系膜缺血患者,比较早期足量抗凝(183例)与未抗凝(187例)的结局。主要终点30天生存率在抗凝组为53.5%,未抗凝组为41.7%(p=0.01),NNT=8;90天生存获益持续(p=0.02)。抗凝组机械通气时间更长(p=0.01),ICU住院时长和出血并发症无差异。多因素Cox模型显示仅早期足量抗凝与血运重建和/或肠切除与生存相关。

要点

  • ICU急性肠系膜缺血患者早期足量抗凝组30天生存率53.5%(98例),未抗凝组41.7%(78例),p=0.01,NNT=8。
  • 早期足量抗凝组90天生存获益持续(p=0.02),出血并发症无差异。
  • 早期足量抗凝组机械通气时间更长(p=0.01),ICU住院时长无差异。
  • 多因素Cox模型显示仅早期足量抗凝与血运重建和/或肠切除与30天生存相关。

适用人群与场景

  • 纳入分析的是ICU住院的急性肠系膜缺血患者,共370例,来自19个国家33个ICU中心。

处置流程与药物剂量

  • 原文指出推荐对急性肠系膜缺血患者尽早开始足量抗凝治疗,不论病因、外科或操作角度、凝血状态如何。
  • 研究中早期足量抗凝组183例接受了早期足量抗凝治疗,未抗凝组187例未接受。

研究设计与关键结果

  • 研究类型为国际多中心研究,纳入19个国家33个ICU中心的370例急性肠系膜缺血患者,比较早期足量抗凝(183例)与未抗凝(187例)。
  • 主要终点30天生存率:早期足量抗凝组53.5%(98例) vs 未抗凝组41.7%(78例),p=0.01,NNT=8。
  • 次要终点:早期足量抗凝组机械通气时间更长(p=0.01);ICU住院时长和出血并发症无差异;90天生存获益持续(p=0.02)。
  • 多因素Cox模型显示仅早期足量抗凝与血运重建和/或肠切除与30天生存相关。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论提示,ICU急性肠系膜缺血患者早期足量抗凝可能带来生存获益,且出血并发症无差异。
  • 原文指出推荐对急性肠系膜缺血患者尽早开始足量抗凝治疗,不论病因、外科或操作角度、凝血状态如何。
  • 原文未报告具体抗凝药物、剂量及疗程,无法据此形成具体用药方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute mesenteric ischemia (AMI) is associated with low survival rates. It is recommended to start early a full dose of anticoagulation therapy in patients with AMI, regardless of etiology, surgical or procedural perspective, or coagulation status. However, there are no international studies addressing the impact of timing and dose of anticoagulation therapy on outcome in AMI patients hospitalized in the intensive care unit (ICU).

METHODS: This international study combined data from 33 ICU centers in 19 countries. The primary outcome was 30-day survival. Secondary outcomes assessed duration of mechanical ventilation, ICU length of stay, occurrence of hemorrhagic complications and 90-day survival. We also identified independent risk factors for 30-day survival.

RESULTS: Among the 370 analyzed patients, 183 received early full-dose anticoagulation therapy and 187 did not. The 30-day survival was 53.5% (n = 98) in patients receiving early full-dose anticoagulation therapy and 41.7% (n = 78) in patients who did not (p = 0.01), with a number needed to treat (NNT) of n = 8. Early full-dose anticoagulation was associated with a longer duration of mechanical ventilation (p = 0.01). No differences were observed in ICU length of stay or hemorrhagic complications. Improved survival persisted in patients receiving early full-dose anticoagulation at 90 day (p = 0.02). We defined four multivariate Cox hazard models for 30-day survival. Only two intervention therapies were associated with survival: early full-dose anticoagulation and revascularization and/or bowel resection.

CONCLUSION: This study suggests a significant survival benefit of early full-dose anticoagulation in ICU patients with acute mesenteric ischemia and no difference in hemorrhagic complications. Early full-dose anticoagulation and revascularization and/or bowel resection were associated with survival.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lakbar I, Delamarre L, Tamme K, et al. Anticoagulation management and outcomes in critically ill patients with acute mesenteric ischemia: an international study. Intensive Care Med. 2025. PMID: 40522480. doi:10.1007/s00134-025-07980-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。